Programme

 

** Please click here to pre-register for The Lancet Diabetes & Endocrinology complimentary places **

Royal College of Physicians, London – Monday 27th November 2017

Chairs:
Professor Derek Yellon
Professor of Molecular & Cellular Cardiology, University College London;
Director of the Hatter Cardiovascular Institute at UCL Hospitals & Medical School, London, UK

Professor Sir John Cunningham
Professor of Nephrology, University College London Medical School and The Royal Free Hospital;
Honorary Fellowship, Trinity Hall, University of Cambridge, UK

Dr Richard HortonEditor-in-Chief, The Lancet, London, UK


Please note that timings are provisional and subject to change.
Monday 27th November - Morning

From 08:00
Badge Collection & Coffee

09:00
The global burden of diabetes
Professor Paul Zimmet
Monash University, Melbourne, Australia

09:40
Therapy for the treatment of type 2 diabetes: out with the old and in with the new?
Professor Naveed Sattar
University of Glasgow, Scotland

10:20
Coffee Break

10:45
The biology and therapeutic potential of GLP-1
Dr Daniel Drucker
University of Toronto, Canada

11:25
The biology and therapeutic potential of SGLT2 inhibition
Professor Bernard Zinman
University of Toronto, Canada

Monday 27th November - Afternoon

12:05
Lunch

13:00
The GLP-1 analogues & DPPIV Inhibitors - cardiovascular outcome benefits for some but not others?
Professor Nikolaus Marx
Aachen University, Germany

13:40
The sodium-glucose co-transporter inhibitors - a cardiologist’s perspective
Professor Lars Rydën
The Karolinska Institute, Stockholm, Sweden

14:20
Sweetening the urine: a new approach to the management of chronic kidney disease
Professor David Wheeler
Royal Free Hospital UCL, London, UK

15:00
Coffee Break

15:25
Let us not forget Metformin!
Professor Cliff Bailey
Aston University, Birmingham, UK

16:05
Combination therapy - the way to go for cardioprotection
Dr Bob Ryder
City Hospital, Birmingham, UK

16:45
Close

The meeting is supported by educational grants and sponsorship from the Pharmaceutical Industry including AstraZeneca; Boehringer Ingelheim; Novo Nordisk, all of whom have provided support for this programme and had no editorial control or influence on the content of the meeting.  Further information can be found here: https://horizonseries.org/hhs-2017/supporters/